Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 8/20 | 0.33 |
| ▸ | PLAU | P00749 | 2/20 | 0.32 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 2/20 | 0.32 |
| ▸ | F7 | P08709 | 1/20 | 0.32 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | KLK1 | P06870 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 5/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13627442 | 0.90 | SETD7 (0.31) | F10SETD7 | |
| SCHEMBL3963938 | 0.90 | SETD7 (0.31) | F10SETD7 | |
| SCHEMBL3963936 | 0.89 | HDAC3 (0.32) | SETD7CNR1 | |
| SCHEMBL3965754 | 0.85 | AHR (0.34) | SETD7PDK2 | |
| SCHEMBL3966628 | 0.82 | HSD17B1 (0.37) | SETD7PDK2 | |
| SCHEMBL3379080 | 0.79 | TRPA1 (0.36) | SETD7PDK2 | |
| SCHEMBL3961355 | 0.79 | BDKRB1 (0.36) | SETD7PDK2 | |
| SCHEMBL3382744 | 0.78 | SETD7 (0.32) | SETD7 | |
| SCHEMBL3382566 | 0.77 | TERT (0.34) | SETD7 | |
| SCHEMBL3965157 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | DAX SCOTT | 2009-11-26 | — | — | US | disclosed |
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | DAX SCOTT | 2009-11-26 | — | — | US | disclosed |
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | DAX SCOTT | 2009-11-26 | — | — | US | disclosed |
| US-7553850-B2 | Tricyclic-bridged piperidinylidene derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA NV (BG) | 2009-06-30 | — | — | US | disclosed |
| US-7553850-B2 | Tricyclic-bridged piperidinylidene derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA NV (BG) | 2009-06-30 | — | — | US | disclosed |
| EP-1910353-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007030089-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-15 | — | — | WO | disclosed |
| US-20060030585-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | OPRD1, OPRK1, OPRM1 | F10 2930/4885PLAU 4854/4885SETD7 3200/4885 |
| US-20060030585-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | F10 2732/4885PLAU 4766/4885SETD7 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.